ST
Starling Oncology, Inc.
STLN · NASDAQ
$6.99 +3.41% (+$0.23)
1M +13.54%
Market Cap $662.9M
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$6.11
12.6% downside
Current Price
$6.99
Undervalued Fair Value Overvalued
According to Bulios Fair Price, STLN is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
100 /100
Cheap P/S 1.13x
P/E N/A
EV/EBITDA N/A
Growth
100 /100
Growing Rev. growth 25.81%
EPS growth N/A
FCF growth N/A
Profitability
5 /100
Weak Gross margin 15.69%
Net margin 6.18%
Op. margin 4.44%
Quality
21 /100
Poor ROIC 28.82%
ROA 20.36%
Asset turnover 3.29x
Debt
27 /100
High Current ratio 1.36x
Int. coverage -3.76x
Debt/Equity N/A
Stability
46 /100
Moderate Beta 0.44x
Rev. volatility 3.92%
EPS volatility 208.70%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about STLN
Online
Sector
Healthcare
Industry
Medical - Care Facilities
CEO
Daniel Virnich
Employees
641
Headquarters
Cerritos